MEDIUM confidence: 100% data completeness, but the composite (42) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-26.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Avg target $536 (last qtr, 6 analysts) → $462 (last mo, 3) (-13.8%).
Buy-rated share 89% → 78% over ~3 months (-11pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Oct 2026 | $3.04 | $3.25 | +6.9% |
| Jul 2026 | $3.09 | $3.23 | +4.5% |
| Apr 2026 | $2.63 | $2.77 | +5.3% |
| Jan 2026 | $2.22 | $2.33 | +5.0% |
| Oct 2025 | $2.13 | $2.43 | +14.1% |
| Jul 2025 | $2.07 | $2.21 | +6.8% |
| Apr 2025 | $1.74 | $1.88 | +8.0% |
| Jan 2025 | $1.56 | $1.66 | +6.4% |
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth above the analyst consensus of 8.4%/yr (revenue basis).
Base free cash flow $276M (avg FY2024–FY2026; latest year $362M) · equity value $14.1B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
Net insider -$60.3M over 180 days (0 open-market buys, 33 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
| Metric (USD) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $1.8B— | $2.6B+38.9% | $2.8B+8.2% | $2.9B+4.3% | $3.1B+8.6% |
| EPS (dil.) | $-1.01— | $1.14n/m | $3.70+224.6% | $7.42+100.5% | $10.52+41.8% |
| Free Cash Flow | -$85M— | -$68Mn/m | $178Mn/m | $286M+60.5% | $362M+26.6% |
| Gross Margin | 8.2% | 13.2%+5.1pp | 21.2%+7.9pp | 26.7%+5.5pp | 30.6%+3.9pp |
| Operating Margin | -1.4% | 5.2%+6.6pp | 11.7%+6.5pp | 18.1%+6.4pp | 22.5%+4.3pp |
| Net Margin | -2.7% | 2.2%+4.9pp | 6.8%+4.5pp | 13.1%+6.3pp | 17.0%+3.9pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
The QScore of 42 for CRS indicates a neutral outlook, with the stock's long-term and short-term scores diverging by 8 points. The stock scores high on profitability, driven by a strong ROE of 26.9% and operating margin of 23.4%, and growth, with revenue growth of 8.6% and EPS growth of 41.4%. However, it exhibits weak momentum, with a 12-month return of -12.5% and a sharply declining 3-month return of -47.9%, which pulls the overall score down.